Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after ...

CVS Health is parting ways with CEO Karen Lynch as the pharmacy giant continues to struggle with problems in its insurance ...

Adi Hoess describes himself as someone who “likes to build” companies focused on “challenging technologies.” It’s fitting, ...

Supernus Pharmaceuticals' mTORC1 activator has cleared a small trial in patients with major depressive disorder, potentially ...

Pfizer's RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the ...

Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to ...

Josh Bilenker and Jeff Engelman's secretive startup Treeline Biosciences has another $421 million, according to a new SEC ...

Amylyx is trying to move forward with its effort to turn its former ALS drug into a treatment for other conditions, and data ...

Shape Therapeutics CEO Francois Vigneault has departed the RNA gene therapy startup, and chief scientific officer David Huss ...

Following a nearly unanimous adcomm against Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, the FDA ...

Amicus Therapeutics resolved a patent dispute with Teva on Thursday, allowing Teva to launch a generic version of its Fabry ...